Paradoxically, although RBM3 supports cellular stress resistance and survival, elevated expression has been linked to favorable prognoses in certain cancer types, including breast cancer [9], bladder cancer [10], gastric and esophageal cancers [11], ovarian cancer [12], prostate cancer [13], and malignant melanoma [14]. This evidence concerns the gene RBM3 and prostate cancer.